Allogene Therapeutics, Inc.

ALLO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$1.69-2.31%

2026-09-18

Financials

Valuation Metrics

Allogene Therapeutics, Inc.'s Market Cap is $583M. At end of 2025 it was $302M. Ranked #2728 of 3,121 in US market (top 87%), #1180 of 1,463 on NASDAQ (top 81%), #218 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$583M	US#2,728/3,121 Sec#218/266
Revenue	$5M	US#2,854/3,121 Sec#181/266
Net Income	$-165M	US—/3,121 Sec—/266
Total Assets	$550M	US#2,735/3,121 Sec#154/266
Net Assets	$436M	US#2,324/3,121 Sec#124/266
Value
P/B	1.34x	US#760/3,121 Sec#28/266
P/S	125.71x	US#2,954/3,121 Sec#182/266
FCF Yield	-17.59%	US—/3,121 Sec—/266
Profitability
ROE	-37.94%	US#2,615/3,121 Sec#129/266
ROA	-30.08%	US#2,885/3,121 Sec#155/266
Op. Margin	-3886.14%	US#2,854/3,121 Sec#177/266
Financial Health
Debt Ratio	26.12%	US#291/3,121 Sec#96/266
Total Debt	$70M	US#2,536/3,121 Sec#139/266
FCF	$-103M	US#2,632/3,121 Sec#145/266
Cash	$39M	US#2,686/3,121 Sec#240/266
Current Ratio	10.72x	US#235/3,121 Sec#73/266
Performance
1Y Return	39.67%	US#537/3,121 Sec#106/266
1M Return	-24.22%	US#2,801/3,121 Sec#217/266
From 52W High	-62.11%	US#2,925/3,121 Sec#236/266
1Y MDD	-45.75%	US#2,278/3,121 Sec#165/266
Trading
Volume	12,187,385 shares	US#432/3,121 Sec#36/266
Trading Value	$21M	US#2,535/3,121 Sec#213/266
Per Share
EPS	$-0.48	US—/3,121 Sec—/266
BPS	$1.26	US#2,661/3,121 Sec#195/266